logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Says US District Court Finds SEROQUEL XR Formulation Patent As Valid

AstraZeneca Plc (AZN: Quote,AZN.L) said Thursday that the US District Court for the District of New Jersey has found the formulation patent protecting SEROQUEL XR (quetiapine fumarate) extended release tablets to be valid.

According to the company, the court has ruled that Anchen Pharmaceuticals Inc., Osmotica Pharmaceutical Corp., Torrent Pharmaceuticals Limited, Torrent Pharma Inc., Mylan Pharmaceuticals Inc., and Mylan Inc. (MYL) have infringed the SEROQUEL XR formulation patent. The SEROQUEL XR formulation patent expires in 2017.

The decision follows a ruling made in the UK on March 22, 2012, which found the formulation patent protecting SEROQUEL XR to be invalid. In the Netherlands, however, on March 7, 2012, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid.

AstraZeneca said it is pleased with the US District Court's decision, which the company believes underlines the strength of its patents.

Seroquel generated $5.83 billion in global sales last year, with $1.4 billion coming from Seroquel XR.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fiat Chrysler Automobiles NV (FCAU) is recalling nearly 26 thousand Chrysler 200s to fix a transmission issue that may prevent the vehicle from shifting into "park." Chrysler said that certain 2015-model year Chrysler 200 vehicles with V6 engines were affected. Chrysler blamed "inconsistent assembly... Gap reported an increase in fourth-quarter profit, as same store sales climbed 11 percent at its Old Navy brand, partly offset by currency impact. Earnings for the quarter topped Wall Street estimates by a penny, while sales were in line with expectations. J.C. Penney Co. Inc. (JCP) Thursday reported a swing to loss in the fourth-quarter from a profit last year, reflecting the absence of benefits from hefty tax gains recorded last year, despite a higher-than-expected revenue growth. Shares of the struggling department store chain plunged a near 10 percent,...
comments powered by Disqus
RELATED NEWS
Trade AZN now with 
Follow RTT